{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:48:39Z","timestamp":1794019719915,"version":"4.8.0"},"reference-count":26,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,6,21]],"date-time":"2020-06-21T00:00:00Z","timestamp":1592697600000},"content-version":"unspecified","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,5,14]]},"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) are associated with rheumatic and musculoskeletal immune-related adverse events (irAEs) in 5%\u201320% of patients. Currently, patients refractory to corticosteroids and conventional disease-modifying antirheumatic drugs (cDMARD) are treated with biological DMARDs (bDMARDs) targeting tumor necrosis factor \u03b1 (TNF\u03b1) and interleukin-6, although without a clear biological rationale. Synovial tissue (ST) biopsy presents a valuable opportunity to investigate irAE pathogenesis and appropriately stratify bDMARD use in refractory irAE patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case presentation<\/jats:title>\n                  <jats:p>We provide the first report of comparative, parallel ST and synovial fluid (SF) analyses of severe, cDMARD-refractory, seronegative polyarthritis, classified as a grade 3 irAE occurring in response to nivolumab treatment for metastatic squamous cell lung cancer, in comparison with ST and SF from patients with untreated rheumatoid arthritis (RA). We investigated immunohistochemical labeling of ST cytokine expression as a biological rationale for selecting therapy. Flow cytometric analysis of lymphocytes from ST, SF and blood collected before and after synovial biopsy-guided therapy, in comparison with RA, were evaluated for insights into the immunopathogenesis of irAE. Immunolabeling of ST demonstrated an excess of TNF\u03b1 cytokine expression. Subsequent treatment with infliximab resulted in resolution of inflammatory symptoms and a significant reduction in C reactive protein levels. Flow cytometric analysis of synovial infiltrates indicated absence of programmed cell death protein-1 (PD-1) receptor positivity despite cessation of nivolumab approximately 200 days prior to the analyzes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A deeper understanding of the immunopathogenetic basis of immune activation in irAEs is required in order to select therapy that is likely to be the most effective. This is the first report investigating parallel blood, ST and SF in ICI-induced severe rheumatic irAE. Use of a bDMARD directed by the dominant inflammatory cytokine achieved resolution of synovitis while maintaining cancer remission.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2019-000281","type":"journal-article","created":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T07:45:13Z","timestamp":1592811913000},"page":"e000281","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":33,"title":["Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy"],"prefix":"10.1136","volume":"8","author":[{"given":"William","family":"Murray-Brown","sequence":"first","affiliation":[{"name":"College of Medicine & Public Health, Flinders University, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom D","family":"Wilsdon","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Flinders Medical Centre, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Weedon","sequence":"additional","affiliation":[{"name":"College of Medicine & Public Health, Flinders University, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Proudman","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Royal Adelaide Hospital, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawgi","family":"Sukumaran","sequence":"additional","affiliation":[{"name":"Oncology Department, Flinders Medical Centre, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Klebe","sequence":"additional","affiliation":[{"name":"College of Medicine & Public Health, Flinders University, Adelaide, South Australia, Australia"},{"name":"SA Pathology at Flinders Medical Centre, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer G","family":"Walker","sequence":"additional","affiliation":[{"name":"College of Medicine & Public Health, Flinders University, Adelaide, South Australia, Australia"},{"name":"Rheumatology Department, Flinders Medical Centre, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm D","family":"Smith","sequence":"additional","affiliation":[{"name":"College of Medicine & Public Health, Flinders University, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6668-9638","authenticated-orcid":false,"given":"Mihir D","family":"Wechalekar","sequence":"additional","affiliation":[{"name":"College of Medicine & Public Health, Flinders University, Adelaide, South Australia, Australia"},{"name":"Rheumatology Department, Flinders Medical Centre, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,6,21]]},"reference":[{"key":"2025100315144402000_8.1.e000281.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.06.001"},{"key":"2025100315144402000_8.1.e000281.2","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"2025100315144402000_8.1.e000281.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016"},{"key":"2025100315144402000_8.1.e000281.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212257"},{"key":"2025100315144402000_8.1.e000281.5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2018.09.027","article-title":"Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: a case series","volume":"105","author":"Mitchell","year":"2018","journal-title":"Eur J Cancer"},{"key":"2025100315144402000_8.1.e000281.6","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.autrev.2018.05.002","article-title":"Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: fasciitis with myositis syndrome as a new complication of immunotherapy","volume":"17","author":"Narv\u00e1ez","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2025100315144402000_8.1.e000281.7","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000412"},{"key":"2025100315144402000_8.1.e000281.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211560"},{"key":"2025100315144402000_8.1.e000281.9","doi-asserted-by":"publisher","DOI":"10.2174\/1381612821666150310145758"},{"key":"2025100315144402000_8.1.e000281.10","doi-asserted-by":"publisher","DOI":"10.1186\/ar4555"},{"key":"2025100315144402000_8.1.e000281.11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192704"},{"key":"2025100315144402000_8.1.e000281.12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183928","article-title":"Triple DMARD treatment in early rheumatoid arthritis modulates synovial T cell activation and plasmablast\/plasma cell differentiation pathways","volume":"12","author":"Walsh","year":"2017","journal-title":"PLoS One"},{"key":"2025100315144402000_8.1.e000281.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"2025100315144402000_8.1.e000281.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780381012"},{"key":"2025100315144402000_8.1.e000281.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.54.8.654"},{"key":"2025100315144402000_8.1.e000281.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1703047"},{"key":"2025100315144402000_8.1.e000281.17","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32835fd8eb"},{"key":"2025100315144402000_8.1.e000281.18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00281-017-0623-3","article-title":"Future therapeutic targets in rheumatoid arthritis?","volume":"39","author":"Cheung","year":"2017","journal-title":"Semin Immunopathol"},{"key":"2025100315144402000_8.1.e000281.19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.tips.2015.02.001","article-title":"Novel therapeutic targets in rheumatoid arthritis","volume":"36","author":"Koenders","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"2025100315144402000_8.1.e000281.20","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0390"},{"key":"2025100315144402000_8.1.e000281.21","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s10067-015-3028-5","article-title":"Follicular helper T cells in rheumatoid arthritis","volume":"34","author":"Yu","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2025100315144402000_8.1.e000281.22","first-page":"313","article-title":"Clinical utility of nivolumab in the treatment of advanced melanoma","volume":"12","author":"Asmar","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"2025100315144402000_8.1.e000281.23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7609"},{"key":"2025100315144402000_8.1.e000281.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"2025100315144402000_8.1.e000281.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0074-9"},{"key":"2025100315144402000_8.1.e000281.26","article-title":"Thinking inside the box: synovial tissue biopsy in immune checkpoint inhibitor-induced arthritis","author":"Medina","year":"2019","journal-title":"J Clin Rheumatol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2019-000281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:14:50Z","timestamp":1759529690000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2019-000281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,6,21]]},"published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1136\/jitc-2019-000281"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2019-000281","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}